Similarly, anti-TNF therapies have been linked to CNS demyelination and increased disease burden in patients with multiple sclerosis with a dose-dependent increase in relapse rate found in a trial of the TNF antagonist lenecept17. The gene discussed is TNF; the disease is multiple sclerosis.